To evaluate the effects of Oxybutynin on double-J stent-related lower urinary tract symptoms following uncomplicated ureterosocpic lithotripsy (URSL).

The double-J ureteral stent had been widely applied during the endourologic surgery to relieve or prevent ureteral obstruction. Some of the patients might encounter stent-related morbidities, such as lower urinary tract symptoms (LUTS), stent related body pain and hematuria, which were bothersome and might have a negative impact on quality of life and sexual performance for both genders Some investigated oral agents such as tolterodine ER (antimuscarinics), tamsulosin and alfuzosin (alpha-1 antagonists) might improve the stent-related symptoms. 
Oxybutynin was a novel antimuscarinics used for treating patients with overactive bladder, and might be effective as well for stent related symptoms, but the evidence is scarce.We conducted a study to evaluate the effectiveness and safety of Oxybutynin for double-J stent related symptoms following uncomplicated ureteroscopic lithotripsy (URSL).

From September 2016 to September 2017, patients underwent double-J ureteral stent insertion following URSL were recruited and received Oxybutynin postoperatively. Another selected subjects without Oxybutynin therapy were enrolled as a control group. The clinical data including stone and stent characteristics and operation time were recorded at admission. All patients completed a validated, structured questionnaire assessing the stent-related lower urinary tract symptoms, body pain and hematuria two weeks after operation. The severity of stent-related symptoms was compared between two groups and for both genders.

The mean age, stone characteristics, stent size, position and curl completeness were all comparable for both groups. Compared to the control group, Oxybutynin cohort had significantly less total symptom scores, item urgency and urgent incontinence subscore. As for stent related body pain, Oxybutynin group had significantly less flank, abdominal, urethral pain and hematuria (all p < 0.001). For Oxybutynin groups of both genders, total symptom scores, item urgent, urgent incontinence and hematuria subscore were all significantly lower than the control group (all p <0.001). Four subjects had minor adverse event and one AUR was encountered following Oxybutynin.

DBJ stent may cause  lower urinary tract symptoms , stent-related body pain and hematuria .
Oxybutynin were effective and well tolerated for those symptoms for patients received DBJ stent insertion.

This prospective study is the first one utilizing age and sex matching, to evaluate the effect of Oxybutynin for stent-related symptoms using validated, structured questionnaire and compared to the control group item by item, for patients following URSL. In the present study, we confirmed that Oxybutynin was effective for stent-related urgency, urgent incontinence, body pain and hematuria for both genders

Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX, Jr., Timoney AG, Barry MJ(2003) Indwelling ureteral stents: Evaluation of symptoms, quality of life and utility. J Urol 169:1065-1069; discussion 1069
Sighinolfi MC, Micali S, De Stefani S, Mofferdin A, Grande M, Giacometti M, Ferrari N, Rivalta M, Bianchi G(2007) Indwelling ureteral stents and sexual health: A prospective, multivariate analysis. J Urol 178:229-231
Damiano R, Autorino R, De Sio M, Cantiello F, Quarto G, Perdona S, Sacco R, D'Armiento M(2005) Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol 48:673-678